Kinase Fusion–Related Thyroid Carcinomas: Towards Predictive Models for Advanced Actionable Diagnostics

Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. The Journal of clinical endocrinology and metabolism. 2006;91:2892-9.

Article  PubMed  CAS  Google Scholar 

Ibrahimpasic T, Ghossein R, Carlson DL, Nixon I, Palmer FL, Shaha AR, et al. Outcomes in patients with poorly differentiated thyroid carcinoma. The Journal of clinical endocrinology and metabolism. 2014;99:1245-52.

Article  PubMed  CAS  Google Scholar 

Wong KS, Dong F, Telatar M, Lorch JH, Alexander EK, Marqusee E, et al. Papillary Thyroid Carcinoma with High-Grade Features Versus Poorly Differentiated Thyroid Carcinoma: An Analysis of Clinicopathologic and Molecular Features and Outcome. Thyroid : official journal of the American Thyroid Association. 2021;31:933-40.

Article  CAS  Google Scholar 

Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. The New England journal of medicine. 2015;372:621-30.

Article  PubMed  Google Scholar 

Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet (London, England). 2014;384:319-28.

Article  PubMed Central  CAS  Google Scholar 

Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 2021;22:1126-38.

Article  PubMed  CAS  Google Scholar 

Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, et al. Cabozantinib in Progressive Medullary Thyroid Cancer. Journal of Clinical Oncology. 2013;31:3639-46.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jr SAW, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, et al. Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial. Journal of Clinical Oncology. 2012;30:134-41

Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Annals of oncology : official journal of the European Society for Medical Oncology. 2022;33:406-15.

Article  CAS  Google Scholar 

Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, et al. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. The New England journal of medicine. 2020;383:825-35.

Article  PubMed  CAS  Google Scholar 

Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. The lancet Diabetes & endocrinology. 2021;9:491-501.

Article  CAS  Google Scholar 

Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, et al. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. European journal of endocrinology. 2022;186:631-43.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. The Lancet Oncology. 2020;21:271-82.

Article  PubMed  CAS  Google Scholar 

Johnson DN, Sadow PM. Exploration of BRAFV600E as a diagnostic adjuvant in the non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Human pathology. 2018;82:32-8.

Article  PubMed  CAS  Google Scholar 

Chu YH, Wirth LJ, Farahani AA, Nosé V, Faquin WC, Dias-Santagata D, et al. Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2020;33:2458-72.

Pekova B, Sykorova V, Dvorakova S, Vaclavikova E, Moravcova J, Katra R, et al. RET, NTRK, ALK, BRAF, and MET Fusions in a Large Cohort of Pediatric Papillary Thyroid Carcinomas. Thyroid : official journal of the American Thyroid Association. 2020;30:1771-80.

Article  CAS  Google Scholar 

Liang J, Cai W, Feng D, Teng H, Mao F, Jiang Y, et al. Genetic landscape of papillary thyroid carcinoma in the Chinese population. The Journal of pathology. 2018;244:215-26.

Article  PubMed  CAS  Google Scholar 

Franco AT, Ricarte-Filho JC, Isaza A, Jones Z, Jain N, Mostoufi-Moab S, et al. Fusion Oncogenes Are Associated With Increased Metastatic Capacity and Persistent Disease in Pediatric Thyroid Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022;40:1081-90.

Article  CAS  Google Scholar 

Lee YA, Lee H, Im SW, Song YS, Oh DY, Kang HJ, et al. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. The Journal of clinical investigation. 2021;131.

Alzahrani AS, Alswailem M, Alswailem AA, Al-Hindi H, Goljan E, Alsudairy N, et al. Genetic Alterations in Pediatric Thyroid Cancer Using a Comprehensive Childhood Cancer Gene Panel. The Journal of clinical endocrinology and metabolism. 2020;105.

Bounacer A, Schlumberger M, Wicker R, Du-Villard JA, Caillou B, Sarasin A, et al. Search for NTRK1 proto-oncogene rearrangements in human thyroid tumours originated after therapeutic radiation. British journal of cancer. 2000;82:308-14.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dinets A, Hulchiy M, Sofiadis A, Ghaderi M, Höög A, Larsson C, et al. Clinical, genetic, and immunohistochemical characterization of 70 Ukrainian adult cases with post-Chornobyl papillary thyroid carcinoma. European journal of endocrinology. 2012;166:1049-60.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Rabes HM, Demidchik EP, Sidorow JD, Lengfelder E, Beimfohr C, Hoelzel D, et al. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000;6:1093-103.

CAS  Google Scholar 

Fenton CL, Lukes Y, Nicholson D, Dinauer CA, Francis GL, Tuttle RM. The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults. The Journal of clinical endocrinology and metabolism. 2000;85:1170-5.

PubMed  CAS  Google Scholar 

Ricarte-Filho JC, Halada S, O'Neill A, Casado-Medrano V, Laetsch TW, Franco AT, et al. The clinical aspect of NTRK-fusions in pediatric papillary thyroid cancer. Cancer genetics. 2022;262-263:57-63.

Article  PubMed  Google Scholar 

Musholt TJ, Musholt PB, Khaladj N, Schulz D, Scheumann GF, Klempnauer J. Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma. Surgery. 2000;128:984-93.

Article  PubMed  CAS  Google Scholar 

Brzeziańska E, Karbownik M, Migdalska-Sek M, Pastuszak-Lewandoska D, Włoch J, Lewiński A. Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population. Mutation research. 2006;599:26-35.

Article  PubMed  Google Scholar 

Lee YC, Hsu CY, Lai CR, Hang JF. NTRK-rearranged papillary thyroid carcinoma demonstrates frequent subtle nuclear features and indeterminate cytologic diagnoses. Cancer cytopathology. 2022;130:136-43.

Article  PubMed  CAS  Google Scholar 

Kong Y, Bu R, Parvathareddy SK, Siraj AK, Siraj N, Al-Sobhi SS, et al. NTRK fusion analysis reveals enrichment in Middle Eastern BRAF wild-type PTC. European journal of endocrinology. 2021;184:503-11.

Article  PubMed  CAS  Google Scholar 

Panebianco F, Nikitski AV, Nikiforova MN, Kaya C, Yip L, Condello V, et al. Characterization of thyroid cancer driven by known and novel ALK fusions. Endocrine-related cancer. 2019;26:803-14.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chou A, Fraser S, Toon CW, Clarkson A, Sioson L, Farzin M, et al. A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. The American journal of surgical pathology. 2015;39:652-9.

Article  PubMed  PubMed Central  Google Scholar 

Park G, Kim TH, Lee HO, Lim JA, Won JK, Min HS, et al. Standard immunohistochemistry efficiently screens for anaplastic lymphoma kinase rearrangements in differentiated thyroid cancer. Endocrine-related cancer. 2015;22:55-63.

Article  PubMed  CAS  Google Scholar 

Nozaki Y, Yamamoto H, Iwasaki T, Sato M, Jiromaru R, Hongo T, et al. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas. Human pathology. 2020;106:82-92.

Article  PubMed  CAS  Google Scholar 

Sisdelli L, Cordioli M, Vaisman F, Moraes L, Colozza-Gama GA, Alves PAG, Jr., et al. AGK-BRAF is associated with distant metastasis and younger age in pediatric papillary thyroid carcinoma. Pediatric blood & cancer. 2019;66:e27707.

Article  Google Scholar 

Efanov AA, Brenner AV, Bogdanova TI, Kelly LM, Liu P, Little MP, et al. Investigation of the Relationship Between Radiation Dose and Gene Mutations and Fusions in Post-Chernobyl Thyroid Cancer. Journal of the National Cancer Institute. 2018;110:371-8.

Article  PubMed  CAS  Google Scholar 

Macerola E, Proietti A, Poma AM, Ugolini C, Torregrossa L, Vignali P, et al. Molecular Alterations in Relation to Histopathological Characteristics in a Large Series of Pediatric Papillary Thyroid Carcinoma from a Single Institution. Cancers. 2021;13.

Bastos AU, de Jesus AC, Cerutti JM. ETV6-NTRK3 and STRN-ALK kinase fusions are recurrent events in papillary thyroid cancer of adult population. European journal of endocrinology. 2018;178:83-91.

Article  PubMed  CAS  Google Scholar 

Prasad ML, Vyas M, Horne MJ, Virk RK, Morotti R, Liu Z, et al. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Cancer. 2016;122:1097-107.

Article  PubMed  CAS  Google Scholar 

Duan H, Li Y, Hu P, Gao J, Ying J, Xu W, et al. Mutational profiling of poorly differentiated and anaplastic thyroid carcinoma by the use of targeted next-generation sequencing. Histopathology. 2019;75:890-9.

Article  PubMed 

留言 (0)

沒有登入
gif